Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 559

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 559
---
.The measure of the reportable segment assets is reported on the balance sheet as total assets. The accounting policies of the reportable segment are the same as those described in Note 2, Summary of Significant Accounting Policies.

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)13. Segment Reporting (Continued)

The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):Year Ended December 31,202420232022Total revenues$661,817 $607,521 $667,238 Less: Significant Segment Expenses:Cost of goods sold77,906 83,779 87,221 Selling153,105 149,955 147,289 Marketing74,188 79,231 120,499 General and administrative94,289 107,175 109,433 Research and development expensesExternal development program expenses:ONAPGO1,641 3,825 1,942 SPN-82027,042 12,311 8,139 SPN-8179,837 9,397 7,341 Qelbree15,819 11,101 8,641 Early-stage programs and other expenses16,352 20,467 16,929 Total external development program expenses70,691 57,101 42,992 Internal employee-related expenses38,105 34,492 31,560 Total research and development expenses108,796 91,593 74,552 Other segment items(a)79,668 94,472 67,533 Net earnings$73,865 $1,316 $60,711 (a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the consolidated statement of earnings.

14. Composition of Other Balance Sheet Items

The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):

Accounts Receivable, NetAs of December 31, 2024, and December 31, 2023, the Company recorded allowances of approximately $12.3 million and $10.7 million, respectively, for prompt pay discount and contractual service fees paid to the Company's customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies. The Company accounts for these